Preámbulo 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition ( 1 ) and in particular Article 13(3) thereof,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) Miyarisan Pharmaceutical Co. Ltd has submitted an application in accordance with Article 13(3) of Regulation (EC) No 1831/2003 proposing to change the name of its EU representative of the holder of the authorisation stated in Commission Regulation (EC) No 903/2009 ( 2 ) and Commission Implementing Regulations (EU) No 373/2011 ( 3 ) , (EU) No 374/2013 ( 4 ) and (EU) No 1108/2014 ( 5 ) .
recital 2recital 2
(2) The applicant claims that Huvepharma NV Belgium has become the new representative for Miyarisan Pharmaceutical Co. Ltd for the feed additive 4b1830 preparation of Clostridium butyricum FERM-BP 2789 with effect from 12 January 2017. The applicant has submitted relevant data supporting its request.
recital 3recital 3
(3) The proposed change of the representative of the holder of the authorisation is purely administrative in nature and does not entail a fresh assessment of the additives concerned. The European Food Safety Authority was informed of the application.
recital 4recital 4
(4) In order to allow Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium to exploit its marketing rights, it is necessary to change the conditions of the respective authorisations. Regulation (EC) No 903/2009, Implementing Regulations (EU) No 373/2011, (EU) No 374/2013 and (EU) No 1108/2014 should therefore be amended accordingly.
recital 5recital 5
(5) Since safety reasons do not require the immediate application of the amendments provided for by this Regulation to Regulation (EC) No 903/2009, Implementing Regulations (EU) No 373/2011, (EU) No 374/2013 and (EU) No 1108/2014, it is appropriate to provide for a transitional period during which existing stocks may be used up.
recital 6recital 6
(6) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plant, Animals, Food and Feed,
Artículo 1Amendment to Regulation (EC) No 903/2009
Regulation (EC) No 903/2009 is amended as follows:
(1) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
(2) In the Annex to Regulation (EC) No 903/2009, in the second column ‘Name of the holder of authorisation’, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Artículo 2Amendment to Implementing Regulation (EU) No 373/2011
Implementing Regulation (EU) No 373/2011 is amended as follows:
(1) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
(2) In the Annex to Implementing Regulation (EU) No 373/2011, in the second column, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Artículo 3Amendment to Implementing Regulation (EU) No 374/2013
Implementing Regulation (EU) No 374/2013 is amended as follows:
(1) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
(2) In the Annex to Implementing Regulation (EU) No 374/2013, in the second column, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Artículo 4Amendment to Implementing Regulation (EU) No 1108/2014
Implementing Regulation (EU) No 1108/2014 is amended as follows:
(1) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
(2) In the Annex to Implementing Regulation (EU) No 1108/2014, in the second column, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
Artículo 5Transitional measures
Existing stocks of the additive, premixtures and compound feed containing the additive, which are in conformity with the provisions applying before the date of entry into force of this Regulation may continue to be placed on the market and used until they are exhausted.
Artículo 6Entry into force
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .